To compare the pharmacology, in vitro activity, and clinical use of the new macrolide antibiotics, azithromycin and clarithromycin, in the treatment of infections caused by mycobacteria other than Mycobacterium tuberculosis.
DATA IDENTIFICATION:
An English-language literature search using MEDLINE (1987–1994), Index Medicus (1987–1994), Program and abstracts of the 31st (1991) and 32nd (1992) Interscience Conference on Antimicrobial Agents and Chemotherapy, and bibliographic reviews of related textbooks, review articles, and professional society publications.
STUDY SELECTION:
105 articles were selected. In vitro and in vivo reports on the pharmacokinetics, microbiology, pharmacology, and effectiveness of clarithromycin and azithromycin were assessed to compare their effectiveness and safety. Emphasis was placed on the use of these new drugs in treating infections caused by Mycobacterium avium complex, Mycobacterium chelonae, and Mycobacterium fortuitum infections.
RESULTS:
A review of the in vitro activity of the new macrolides revealed moderate to very good activity against many strains of mycobacteria other than M. tuberculosis. Early clinical trials show promising results in pulmonary infections, lymphadenitis, cutaneous infections, and disseminated infections.
CONCLUSIONS:
The new macrolides, azithromycin and clarithromycin, show great promise for treating infections caused by these acid-fast bacteria. Clarithromycin is recommended as a component of combination therapy for the treatment of M. avium complex infections in patients with AIDS. The development of resistance in patients, particularly when these agents are used alone, has been reported.
Get full access to this article
View all access options for this article.
References
1.
WoodsGLWashingtonJA. Mycobacteria other than Mycobacterium tuberculosis: Review of microbiologic and clinical aspects. Rev Infect Dis1987; 9: 275–94.
2.
WolinskyE. Mycobacterial diseases other than tuberculosis. Clin Infect Dis1992; 15: 1–12.
3.
Diagnosis and treatment of disease caused by nontuberculosis mycobacteria 1990. Official Statement of the American Thoracic Society and the American Lung Association. Am Rev Resp Dis1990; 142: 940–53.
4.
BatesJH. A study of pulmonary disease associated with mycobacteria other than M. tuberculosis: Clinical characteristics. Am Rev Respir Dis1967; 96: 1151–7.
5.
YeagerHRaleighJW. Pulmonary disease due to Mycobacterium intracellulareAm Rev Respir Dis1973; 108: 547–52.
6.
RunyonEH. Whence mycobacteria and mycobacterioses. Ann Intern Med1971; 75: 467–8.
7.
RosenzweigDX. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Chest1979; 75: 115–9.
8.
WolinskyE. Mycobacterial diseases other than tuberculosis. Clin Infect Dis1992; 15: 1–12.
9.
MahmoudiAIsemanMD. Pitfalls in the care of patients with tuberculosis: Common errors and their association with the acquisition of drug resistance. JAMA1993; 270: 65–8.
10.
WolinskyE. Statement of the Tuberculosis Committee of the Infectious Diseases Society of America. Clin Infect Dis1993; 16: 627–8.
11.
HooverDRSaahAJBacellarHPhairJDetelsRAndersonR. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med1993; 329: 1922–6.
12.
RubinRHTolkoff-RubinNE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother1993; 37: 619–24.
13.
SafranekTJJarvisWRCarsonLSCrusickLBBlandLASwensonJM. Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution. N Engl J Med1987; 317: 197–201.
14.
SteadmanJE. High-catalase strains of Mycobacterium kansasii isolated from water in Texas. J Clin Microbiol1980; 11: 135–49.
15.
GrulfHFalkinhamJOParkerBC. Recent experience in the epidemiology of disease caused by atypical mycobacteria. Rev Infect Dis1981; 3: 990–6.
16.
ReznikofMLeggoJHDawsonDJ. Investigation by seroagglutination of strains of the Mycobacterium intracellulare—M. scrofulaceum group from house dusts and sputum in southeastern Queensland. Am Rev Respir Dis1974; 104: 951–3.
17.
CollinsCHGrangeJMNobleWCYatesMD. Mycobacterium marinum infections in man. J Hygiene1985; 94: 135–49.
18.
BlackMMEykynS. The successful treatment of tropical fish tank granuloma (Mycobacterium marinum infections). Arch Intern Med1986; 146: 902–4.
19.
BanksJHunterAMCampbellIAJenkinsPASmithAP. Pulmonary infection with Mycobacterium kansasii in Wales 1970–79: Review of treatment and response. Thorax1983; 38: 271–4.
20.
FrancisPBJaySJJohansonWG. Course of untreated M. kansasii disease. Am Rev Respir Dis1975; 111: 477–87.
21.
ParrotRGGrossetJH. Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection. Tubercle1988; 69: 47–55.
22.
BanksJHunterAMCampbellIAJenkinsPASmithAP. Pulmonary infection with Mycobacterium xenopi: Review of treatment and response. Thorax1984; 39: 376–82.
23.
O'BrienRJGeiterLMSniderDE. The epidemiology of nontuberculous mycobacterial disease in the United States: Results from a national survey. Am Rev Respir Dis1987; 135: 1004–14.
24.
HawkinsCCGoldJWMWhimbeyEKiehnTEBrannonPCammarataR. Mycobacterium-avium complex infections in patients with acquired immunodeficiency syndrome. Ann Intern Med1986; 105: 184–8.
25.
GirardAEGirardDEnglishARGootzTOCimochowskiCRFaiellaJA. Pharmacokinetics and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother1987; 31: 1948–54.
26.
PruulHWetherallBMcDonaldPJ. In vitro killing of erythromycin-exposed group A streptococci by polymorphonuclear leukocytes. Eur J Clin Microbiol1986; 5: 405–10.
27.
Van der AuweraPMatsumotoTHussonM. Intraphagocytic penetration of antibiotics. J Antimicrob Chemother1988; 22: 185–92.
28.
IshiguroMKogaHKohnoSHagashiTYamaguchiKHirotaM. Penetration of macrolides into human polymorphonuclear leukocytes. J Antimicrob Chemother1989; 24: 719–29.
29.
PruulHMcDonaldPJ. Potentiation of the antibacterial activity of azithromycin by normal human serum. Antimicrob Agents Chemother1992; 36: 10–6.
30.
PruulHWetherallBLMcDonaldPJ. The susceptibility of antibiotic pretreated gram-negative bacteria to the bactericidal activity of human neutrophil granule extract. In: EickenbertHUHamHOpferkuchW eds. The influence of antibiotics on the host—parasite relationship. Heidelberg: Springer-Verlag, 1982: 208–18.
31.
CohenYPerronneCTruffot-PernotCGrossetJVildeLLPocidaloJJ. Activities of WIN-57273, minocycline, clarithromycin, and 14 hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother1992; 36: 2104–7.
32.
GladueRPBrightGMIsaacsonRENewborgMF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother1989; 33: 277–82.
33.
PerronneCGikasATruffot-PernotCGrossetJVildeJLPocidaloJJ. Activities of sparfloxacin, azithromycin, temafloxacin, and rifabutin compared with that of clarithromycin against multiplication of Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother1991; 35: 1356–9.
34.
ButlerWRAhernDGKilburnJO. High performance liquid chromatography of mycolic acids as a tool in the identification of Corynebacterium, Norcardia, Rhodococcus, and Mycobacterium species. J Clin Microbiol1986; 23: 884–5.
35.
GarbeTHarrisDVordermeierMLathigraRIvanyiJYoungD. Expression of the Mycobacterium tuberculosis 19-kilodalton antigen in Mycobacterium smegmatis: Immunological analysis and evidence of glycosylation. Infect Immun1993; 61: 260–7.
36.
NairJRoseDAMorrisSL. Nucleotide sequence analysis and serologic characterization of a 27-kilodalton Mycobacterium intracellulare lipoprotein. Infect Immun1993; 61: 1074–81.
37.
BoothRJWilliamsDLMoudgilKDNoonanLCGrandisonPMMcKeeJJ. Homologs of Mycobacterium leprae 18-kilodalton and Mycobacterium tuberculosis 19-kilodalton antigen in other mycobacteria. Infect Immun1993; 61: 1509–15.
38.
KardoryNRolstonKRosenbaumSHayatSBodeyGP. Comparative in vitro activity of twenty antimicrobial agents against clinical isolates of Mycobacterium avium complex. J Antimicrob Chemother1989; 24: 667–73.
39.
InderliedCBYoungLSYamadaJK. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother1987; 31: 1697–702.
40.
HorsburghCRMasonUGHeifetsLBSouthwickJLIsemanMD. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis1987; 135: 418–21.
41.
LallaFMaseratiRScarpelleniPMaronePNocolinRCaccamoF. Clarithromycin-ciprofloxacin-amikacín for therapy of Mycobacterium avium—Mycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob Agents Chemother1992; 36: 1567–9.
42.
ArbeitRDSlutskyABarberTWMaslowJNNiemczykSFalkinhamJO. Genetic diversity among strains of Mycobacterium avium causing monoclonal and polyclonal bacteremia in patients with AIDS. J Infect Dis1993; 167: 1384–90.
43.
SwensonJMWallaceRJSilcoxVAThornsberryC. Antimicrobial susceptibility testing of 5 subgroups of Mycobacterium fortuitum and Mycobacterium chelonaeAntimicrob Agents Chemother1985; 28: 807–11.
44.
StoneMSWallaceRJSwensonJMThornsberryCChristensenLA. An agar disk elution method for clinical susceptibility testing of Mycobacterium marinum and the Mycobacterium fortuitum-complex to sulfonamides and antibiotics. Antimicrob Agents Chemother1983; 24: 486–93.
BallowCHAmsdenGW. Azithromycin: The first azalide antibiotic. Ann Pharmacother1992; 26: 1253–61.
47.
HopkinsS. Clinical toleration and safety of azithromycin. Am J Med1991; 9 (suppl 3A):40S–5S.
48.
ItohZSuzukiTNakayaMInoueMMitsuhashiS. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother1984; 26: 863–9.
49.
MouraSTsuzukiKSunazukaTMaruiSToyodaH. Macrolides with gastrointestinal motor stimulating activity. J Med Chem1987; 30: 1941–3.
50.
ItohZNakayaMTomoakiTInoueMAraiHWakabayashiK. Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. Am J Physiol1985; 11: 320–5.
51.
NaikSRuckR. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother1989; 33: 1614–6.
52.
HeifetsLBLindholm-LevyPJComstockDR. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium aviumAm Rev Resp Dis1992; 145: 856–8.
53.
MorNHeifetsL. Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. Antimicrob Agents Chemother1993; 37: 1380–2.
54.
MorNHeifetsL. MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother1993; 37: 111–4.
55.
PerronneCGikasATruffot-PernotCGrossetJPocidaloJJVildeJL. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother1990; 34: 1508–11.
56.
YajkoDMNassosPSSandersCAGonzalezDCHadleyWK. Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type I infected individuals. Antimicrob Agents Chemother1992; 36: 1163–5.
57.
RastogiNLabrousseV. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother1991; 35: 462–70.
58.
RastogiNLabrousseVGohKSCarvalhoDESousaJP. Antimycobacterial spectrum of Sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob Agents Chemother1991; 35: 2473–80.
59.
BrownBAWallaceRJOnyiGO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother1992; 36: 1987–90.
60.
GayJDDeYoungDRRobertsGD. In vitro activities of norfloxacin and ciprofloxacin againstAntimicrob Agents Chemother1984; 26: 94–6.
61.
BrownBAWallaceRJOnyiGODerosasVWallaceRJ. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother1992; 36: 180–4.
62.
SiebertAFBassJB. Four drug therapy of pulmonary disease due to Mycobacterium avium complex (abstract). Am Rev Respir Dis1989; 139: A399.
63.
AndersonRJooneGVan RensburgEJ. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide. J Antimicrob Chemother1988; 22: 923–33.
64.
AndersonRVan RensburgCEJJooneGLukeyPT. An in vitro comparison of the intraphagocytic activity of erythromycin and roxithromycin. J Antimicrob Chemother1987; 20 (suppl B):57–68.
65.
RaghoebarMLindeyerEVan DenbergWBCeesAMGinnekenV. On the mechanisms of association of the macrolide antibiotic erythromycin with isolated human polymorphonuclear leukocytes. Biochem Pharmacol1988; 37: 3221–7.
66.
ProkeschRCHandWL. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother1982; 21: 373–80.
DetteGAKnotheH. Kinetics of erythromycin uptake and release by human lymphocytes and polymorphonuclear leukocytes. J Antimicrob Chemother1986; 18: 73–82.
69.
GlaudeRPSniderME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother1990; 34: 1056–60.
70.
FernandesPBHardyDJMcDanielDHansonCWSwansonRN. In vitro and in vivo activities of clarithromycin against Mycobacterium aviumAntimicrob Agents Chemother1989; 33: 1531–4.
71.
AhnCHAhnSSAndersonRAMurphyDTMammoA. A four drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium-complex. Am Rev Respir Dis1986; 134: 438–41.
72.
KemperCAMengTCNussbaumJChiuJFeigalDFBartokAE. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Ann Intern Med1992; 116: 466–72.
73.
RastogiNFrehelCRyterAOhayonHLesourdMDavidHL. Multiple drug resistance in Mycobacterium avium: Is the wall architecture responsible for the exclusion of antimicrobial agents? Antimicrob Agents Chemother1981; 20: 666–77.
74.
ChaissonRBensonCDubeMHafnerRDellersonMLichterS. Clarithromycin (CLR) treatment for disseminated Mycobacterium avium complex disease (DMAC) in AIDS (abstract). Presented at the International Conference on AIDS, Amsterdam, 1992.
75.
DautzenbergBTruffotCLegrisSMeyohasMCBerlieHCMercatA. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis1991; 144: 564–9.
76.
DautzenbergBMarcSMeyohasMCEliaszewitchMHaniezFRoquesAM. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med1993; 153: 368–72.
77.
RufB. Acquired resistance of MAI to clarithromycin (letter). Am Rev Respir Dis1991; 144: 1241.
78.
YoungLSWiviottLWuMKolonoskiPBolanRInderliedCB. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet1992; 338: 1107–9.
79.
BensonCAEllnerJJ. Mycobacterium avium complex infection and AIDS: Advances in theory and practice. Clin Infect Dis1993; 17: 7–20.
80.
Masur H, Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virusN Engl J Med1993; 329: 898–904.
81.
BolanGReingoldALCarsonLASilcoxVAWoodleyCLHayesPS. Infections with Mycobacterium chelonae in patients receiving dialysis and using processed hemodialyzers. J Infect Dis1985; 152: 1013–9.
82.
LaussucqSBaltchALSmithRPSmithwickRWDavisBJDesjardinEK. Nosocomial Mycobacterium fortuitum colonization from a contaminated ice machine. Am Rev Respir Dis1988; 139: 891–4.
83.
LowryPWJarvisWROberleADBlandLASilbermanRBocchiniJA. Mycobacterium chelonae causing otitis media in an ear-nose-and-throat practice. N Engl J Med1988; 319: 978–82.
84.
SzaboISarkoziK. Mycobacterium chelonae endemy after heart surgery with fatal consequences. Am Rev Respir Dis1980; 121: 607.
85.
HoffmanPCFraserDWRobicsekFOlbarPRMauneyCU. Two outbreaks of sternal wound infections due to organisms of the Mycobacterium fortuitum complex. J Infect Dis1981; 143: 533–42.
86.
WallaceRJ. The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteriaChelonae. Clin Chest Med1989; 10: 419–29.
DalovisiaJRPankeyGAWallaceRJJonesDB. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonaeRev Infect Dis1981; 3: 1068–74.
89.
BrownBAWallaceRJOnyiGODe RosasVWallaceRJIII. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother1992; 36: 180–4.
90.
FranckNCabieAVilletteBAmorBLessana-LeibowitzMEscandeJP. Treatment of Mycobacterium chelonae-induced skin infection with clarithromycin. J Am Acad Dermatol1993; 28: 1019–21.
91.
WallaceRJTannerDBrennanPJBrownBACraftJCBlahunkaK. Preliminary results of an open noncomparative trial of clarithromycin in the therapy of (disseminated) infection due to Mycobacterium chelonae subsp. chelonae (Mcc). Presented at the First International Conference on Macrolides, Azalides, and Streptogramins, Sante Fe, New Mexico, 1992.
92.
WallaceRJBrownBATannerDBrennanPJBlahunkaKSCraftJC. An open trial of clarithromycin in therapy of (disseminated) cutaneous infection due to Mycobacterium chelonae subsp chelonae (abstract). Presented at the AIDS International Conference, Amsterdam, 1992.
93.
DautzenbergBLabeilleBBalloulHDeLavePHSchmidtJLTruffotCH. Clarithromycin in ten patients with Mycobacterium chelonae infections. Presented at the First International Conference on the Macrolides, Azalides, and Streptogramins. Sante Fe, New Mexico, 1992.
